← Leaderboards
Sujit Basu
Mayo Clinic Rochester
$9,062,631
Attributed
$9,237,487
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,237,487 · 9
By mechanism
R01$8,934,225 · 8
R21$303,262 · 1
Top collaborators
- Xue-Feng Bai1 shared
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingPathway InteractionsReceptorTissuesReportingPlayExperimental DesignsCellsDopamineMalignant NeoplasmsStem CellsCyclic Amp-Dependent Protein KinasesGrowthTreatment EfficacyNeovascularizationTumorBone MarrowSignal PathwayAnimalsEndothelial CellsResearch StudyRegulationEffective TherapyDesign
Grant awards (28)
CD200R blockade for cancer immunotherapy$673,569
R01 · FY2025 · CA · contact PI
A new therapeutic strategy to target liver metastasis in colon cancer$460,985
R01 · FY2025 · CA · contact PI
CD200R blockade for cancer immunotherapy$559,062
R01 · FY2024 · CA · contact PI
IL-27 as a potential immunotherapeutic for cancer$349,713
R01 · FY2023 · CA · contact PI
IL-27 as a potential immunotherapeutic for cancer$349,713
R01 · FY2022 · CA · contact PI
CD200R signaling in tumor growth, immunity and immunotherapy$349,713
R01 · FY2022 · CA · contact PI
Role of chebulinic acid in angiogenesis$385,000
R01 · FY2019 · HL · contact PI
Role of chebulinic acid in angiogenesis$385,000
R01 · FY2018 · HL · contact PI
Role of chebulinic acid in angiogenesis$385,000
R01 · FY2017 · HL · contact PI
Dopamine as a therapeutic agent in stomach cancer$319,550
R01 · FY2017 · CA · contact PI
Role of chebulinic acid in angiogenesis$385,000
R01 · FY2016 · HL · contact PI
Role of dopamine in the regulation of endothelial cell functions in diabetes$331,688
R01 · FY2016 · DK · contact PI
Dopamine as a therapeutic agent in stomach cancer$319,550
R01 · FY2016 · CA · contact PI
Role of dopamine in the regulation of endothelial cell functions in diabetes$331,688
R01 · FY2015 · DK · contact PI
Dopamine as a therapeutic agent in stomach cancer$319,550
R01 · FY2015 · CA · contact PI
Role of dopamine in the regulation of endothelial cell functions in diabetes$331,688
R01 · FY2014 · DK · contact PI
Dopamine as a therapeutic agent in stomach cancer$309,628
R01 · FY2014 · CA · contact PI
Role of dopamine in the regulation of endothelial cell functions in diabetes$320,079
R01 · FY2013 · DK · contact PI
Dopamine as a therapeutic agent in stomach cancer$317,821
R01 · FY2013 · CA · contact PI
Role of dopamine in the regulation of endothelial cell functions in diabetes$331,688
R01 · FY2012 · DK · contact PI
The Role of Dopamine in Colon Cancer Neovascularization$276,450
R01 · FY2011 · CA · contact PI
The Role of Dopamine in Colon Cancer Neovascularization$285,000
R01 · FY2010 · CA · contact PI
The Role of Dopamine in Colon Cancer Neovascularization$282,910
R01 · FY2009 · CA · contact PI
The Role of Dopamine in Colon Cancer Neovascularization$285,000
R01 · FY2008 · CA · contact PI
The Role of Dopamine in Colon Cancer Neovascularization$2,090
R01 · FY2008 · CA · contact PI
The Role of Dopamine in Colon Cancer Neovascularization$287,090
R01 · FY2007 · CA · contact PI
The Neurotransmitter Dopamine and Gastric Cancer$135,637
R21 · FY2007 · CA · contact PI
The Neurotransmitter Dopamine and Gastric Cancer$167,625
R21 · FY2006 · CA · contact PI